Het traject van vasculaire biologie naar de kliniek: inflammatie verminderen verlaagt het CV risico
Inflammation expert opinions
10' educatie - 20 sep. 2017Video navigation menu
CV event reduction as a consequence of lowering inflammation: top-line results of the CANTOS-trial 0:38
The beginning of vascular biology research on the inflammation hypothesis 1:10
Translation of experimental research into clinical application 3:10
What are the potential adverse effects of inhibiting IL-1β and how might they be mitigated? 5:15
'Adverse events' in the CANTOS trial also include favorable side-effects 6:19
Considering the CANTOS results, where should we go from here? 7:15
Educatieve informatie
Deze video werd geproduceerd als een educatieve service door PACE-CME met als doel om een expert perspectief te geven op nieuwe ontwikkelingen zoals de presentatie van de CANTOS studie (The Canakinumab Anti-inflammatory Thrombosis Outcomes Study). Bezoek ook voor meer informatie en andere internationale expert opinions ook PACE-CME.org
Disclosures
Prof. Paul Ridker - is director of the Center for Cardiovascular Disease Prevention, a translational research unit at Brigham and Women’s Hospital. A cardiovascular medicine specialist, and Eugene Braunwald Professor of Medicine at Harvard School of Medicine.
Prof. Peter Libby - is Senior Advisor, Center for Interdisciplinary Cardiovascular Sciences; Mallinckrodt Professor of Medicine, Harvard Medical School; Senior Physician, Brigham and Women's Hospital, Boston, MA, USA
Funding
Funding to produce this video was provided by an unrestricted educational grant from Novartis.
Deel deze pagina met collega's en vrienden: